EP1998266A3 - Method for identification of T-cell epitopes and use for preparing molecules with reduced immunogenicity - Google Patents

Method for identification of T-cell epitopes and use for preparing molecules with reduced immunogenicity Download PDF

Info

Publication number
EP1998266A3
EP1998266A3 EP08011838A EP08011838A EP1998266A3 EP 1998266 A3 EP1998266 A3 EP 1998266A3 EP 08011838 A EP08011838 A EP 08011838A EP 08011838 A EP08011838 A EP 08011838A EP 1998266 A3 EP1998266 A3 EP 1998266A3
Authority
EP
European Patent Office
Prior art keywords
identification
cell epitopes
reduced immunogenicity
novel
preparing molecules
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP08011838A
Other languages
German (de)
French (fr)
Other versions
EP1998266A2 (en
Inventor
Francis Joseph Dr. Carr
Graham Carter
Tim Dr. Jones
Anita A. Hamilton
Stephen Williams
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Priority to EP08011838A priority Critical patent/EP1998266A3/en
Publication of EP1998266A2 publication Critical patent/EP1998266A2/en
Publication of EP1998266A3 publication Critical patent/EP1998266A3/en
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • C07K16/465—Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7015—Drug-containing film-forming compositions, e.g. spray-on
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
    • G16B15/20—Protein or domain folding
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/50—Mutagenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biotechnology (AREA)
  • Theoretical Computer Science (AREA)
  • Medical Informatics (AREA)
  • Evolutionary Biology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

This invention relates to a novel approach for identification of T-cell epitopes, that give rise to an immune reaction in a living host. By means of this novel method biological compounds can be generated which have a no or at least a reduced immunogenicity when exposed to the immune system of a given species and compared with the relevant non-modified entity. Thus the invention relates also to novel biological molecules, especially proteins and antibodies, obtained by the method according to the invention.
EP08011838A 2001-02-19 2002-02-18 Method for identification of T-cell epitopes and use for preparing molecules with reduced immunogenicity Withdrawn EP1998266A3 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP08011838A EP1998266A3 (en) 2001-02-19 2002-02-18 Method for identification of T-cell epitopes and use for preparing molecules with reduced immunogenicity

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
EP01103954 2001-02-19
EP01105777 2001-03-08
EP01106536 2001-03-15
EP01106538 2001-03-15
EP01106899 2001-03-20
EP01107012 2001-03-20
EP01107568 2001-03-27
EP01110220 2001-04-25
EP01113228 2001-05-30
EP01124965 2001-10-19
EP01126859 2001-11-12
EP08011838A EP1998266A3 (en) 2001-02-19 2002-02-18 Method for identification of T-cell epitopes and use for preparing molecules with reduced immunogenicity
EP02726112A EP1366455B1 (en) 2001-02-19 2002-02-18 Method for identification of t-cell epitopes and use for preparing molecules with reduced immunogenicity

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
EP02726112A Division EP1366455B1 (en) 2001-02-19 2002-02-18 Method for identification of t-cell epitopes and use for preparing molecules with reduced immunogenicity

Publications (2)

Publication Number Publication Date
EP1998266A2 EP1998266A2 (en) 2008-12-03
EP1998266A3 true EP1998266A3 (en) 2009-02-11

Family

ID=27581535

Family Applications (2)

Application Number Title Priority Date Filing Date
EP02726112A Expired - Lifetime EP1366455B1 (en) 2001-02-19 2002-02-18 Method for identification of t-cell epitopes and use for preparing molecules with reduced immunogenicity
EP08011838A Withdrawn EP1998266A3 (en) 2001-02-19 2002-02-18 Method for identification of T-cell epitopes and use for preparing molecules with reduced immunogenicity

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP02726112A Expired - Lifetime EP1366455B1 (en) 2001-02-19 2002-02-18 Method for identification of t-cell epitopes and use for preparing molecules with reduced immunogenicity

Country Status (14)

Country Link
US (1) US7430476B2 (en)
EP (2) EP1366455B1 (en)
JP (1) JP4279554B2 (en)
KR (1) KR100899970B1 (en)
CN (1) CN100404673C (en)
AT (1) ATE400030T1 (en)
AU (1) AU2002256624B2 (en)
CA (1) CA2438652A1 (en)
ES (1) ES2309167T3 (en)
HU (1) HUP0303199A2 (en)
MX (1) MXPA03007316A (en)
PL (1) PL362414A1 (en)
WO (1) WO2002069232A2 (en)
ZA (1) ZA200307324B (en)

Families Citing this family (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2312188C (en) 1997-12-08 2010-06-29 Lexigen Pharmaceuticals Corp. Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation
CA2328076C (en) * 1998-04-15 2009-10-06 Lexigen Pharmaceuticals Corporation Enhancement of antibody-cytokine fusion protein mediated immune responses by co-administration with angiogenesis inhibitor
EP1179186B1 (en) * 1999-05-14 2006-01-11 McGill University Method for identifying modulators of interacting proteins
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
DK1200479T3 (en) * 1999-08-09 2006-05-15 Emd Lexigen Res Ct Corp Multiple cytokine-antibody complexes
MXPA02012734A (en) * 2000-06-29 2003-04-25 Merck Patent Gmbh Enhancement of antibody-cytokine fusion protein mediated immune responses by combined treatment with immunocytokine uptake enhancing agents.
US20090137416A1 (en) 2001-01-16 2009-05-28 Regeneron Pharmaceuticals, Inc. Isolating Cells Expressing Secreted Proteins
KR100900176B1 (en) 2001-03-07 2009-06-02 메르크 파텐트 게엠베하 Expression technology for proteins containing a hybrid isotype antibody moiety
US6992174B2 (en) 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
CA2446087C (en) 2001-05-03 2013-06-18 Stephen D. Gillies Recombinant tumor specific antibody and use thereof
DK200101090A (en) * 2001-07-12 2001-08-16 Novozymes As Subtilase variants
CN1585778A (en) * 2001-11-12 2005-02-23 默克专利有限公司 Modified anti-TNF alpha antibody
US20050074863A1 (en) * 2001-11-29 2005-04-07 Koen Hellendoorn T-cell epitodes in carboxypeptidase g2
AU2002357784B2 (en) 2001-12-04 2008-07-31 Merck Patent Gmbh Immunocytokines with modulated selectivity
JP4597528B2 (en) * 2002-02-26 2010-12-15 ジェネンコー・インターナショナル・インク Subtilisin Carlsberg protein with reduced immunogenicity
RU2004139047A (en) * 2002-06-11 2006-01-20 Мерк Патент ГмбХ (DE) MODIFIED BRIODIN 1 WITH REDUCED IMMUNOGENITY
CN1675242A (en) * 2002-08-09 2005-09-28 默克专利有限公司 T-cell epitopes in erythropoietin
WO2004039832A2 (en) * 2002-10-31 2004-05-13 Albany Medical College Leptin-related peptides
JP4966497B2 (en) * 2002-11-15 2012-07-04 ゲンマブ エー／エス Human monoclonal antibody against CD25
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
AU2004245038A1 (en) * 2003-06-02 2004-12-16 Alexion Pharmaceuticals, Inc. De-immunized anti-CD3 antibody
EP1636264A2 (en) * 2003-06-24 2006-03-22 MERCK PATENT GmbH Tumour necrosis factor receptor molecules with reduced immunogenicity
US8147832B2 (en) * 2003-08-14 2012-04-03 Merck Patent Gmbh CD20-binding polypeptide compositions and methods
US20050069521A1 (en) * 2003-08-28 2005-03-31 Emd Lexigen Research Center Corp. Enhancing the circulating half-life of interleukin-2 proteins
US8883147B2 (en) 2004-10-21 2014-11-11 Xencor, Inc. Immunoglobulins insertions, deletions, and substitutions
US9714282B2 (en) 2003-09-26 2017-07-25 Xencor, Inc. Optimized Fc variants and methods for their generation
US8399618B2 (en) 2004-10-21 2013-03-19 Xencor, Inc. Immunoglobulin insertions, deletions, and substitutions
DK1673398T3 (en) 2003-10-16 2011-04-18 Micromet Ag Multispecific, deimmunized CD3 binders
EP1694706B1 (en) * 2003-11-01 2012-04-04 Merck Patent GmbH Modified anti-cd52 antibody
EP1697741A4 (en) 2003-12-04 2008-02-13 Xencor Inc Methods of generating variant proteins with increased host string content and compositions thereof
US20060122783A1 (en) * 2004-08-24 2006-06-08 Ishikawa Muriel Y System and method for heightening a humoral immune response
US20050164308A1 (en) * 2003-12-18 2005-07-28 Fiona Harding Beta-lactamase CD4+ T-cell epitopes
BRPI0418286A (en) * 2003-12-30 2007-05-02 Merck Patent Gmbh il-7 fusion proteins
WO2005063808A1 (en) * 2003-12-31 2005-07-14 Merck Patent Gmbh Fc-ERYTHROPOIETIN FUSION PROTEIN WITH IMPROVED PHARMACOKINETICS
CA2553883C (en) * 2004-01-22 2013-04-02 Merck Patent Gesellschaft Mit Beschraenkter Haftung Anti-cancer antibodies with reduced complement fixation
PT1737961E (en) * 2004-03-19 2013-08-26 Merck Patent Gmbh Modified bouganin proteins, cytotoxins and methods and uses thereof
EP2053062A1 (en) 2004-03-24 2009-04-29 Xencor, Inc. Immunoglobin variants outside the Fc region
US7670595B2 (en) * 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
WO2006019447A1 (en) 2004-07-15 2006-02-23 Xencor, Inc. Optimized fc variants
US20060073563A1 (en) * 2004-09-02 2006-04-06 Xencor, Inc. Erythropoietin derivatives with altered immunogenicity
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
EP2845865A1 (en) 2004-11-12 2015-03-11 Xencor Inc. Fc variants with altered binding to FcRn
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
KR20070085886A (en) * 2004-12-09 2007-08-27 메르크 파텐트 게엠베하 Il-7 variants with reduced immunogenicity
AU2012209017B2 (en) * 2005-02-03 2014-06-26 Antitope Limited Human antibodies and proteins
AU2006210724A1 (en) * 2005-02-03 2006-08-10 Antitope Limited Human antibodies and proteins
AU2006299429B2 (en) 2005-10-03 2012-02-23 Xencor, Inc. Fc variants with optimized Fc receptor binding properties
PT1966238E (en) * 2005-12-30 2012-07-31 Merck Patent Gmbh Interleukin-12p40 variants with improved stability
DK2270050T3 (en) * 2005-12-30 2013-08-12 Merck Patent Gmbh Anti-CD19 antibodies with reduced immunogenicity
DK2463305T3 (en) 2006-01-12 2016-08-29 Alexion Pharma Inc Antibodies to OX-2 / CD200 and uses thereof
US20080095756A1 (en) * 2006-09-05 2008-04-24 Biosynexus Incorporated Compositions Comprising Lysostaphin Variants And Methods Of Using The Same
WO2008157776A2 (en) * 2007-06-21 2008-12-24 Angelica Therapeutics, Inc. Modified diphtheria toxins
CA2693863C (en) 2007-07-17 2017-10-03 Merck Patent Gmbh Engineered anti-alpha v- integrin hybrid antibodies
CA2696339C (en) 2007-08-22 2017-12-19 Probiogen Ag Culture system and method for immunogenicity and immunofunction testing in vitro
HUE024903T2 (en) 2007-12-26 2016-02-29 Xencor Inc Fc variants with altered binding to fcrn
EP2268297A4 (en) * 2008-02-29 2011-11-16 Angelica Therapeutics Inc Modified toxins
NO2700405T3 (en) 2008-05-29 2018-09-01
SI2894165T1 (en) 2008-11-10 2023-04-28 Alexion Pharmaceuticals, Inc. Methods and compositions for treating complement-associated disorders
CN102405230A (en) * 2009-04-22 2012-04-04 默克专利有限公司 Antibody fusion proteins with modified fcrn binding sites
WO2010124262A1 (en) * 2009-04-24 2010-10-28 Allostera Pharma Inc. Methods of identification of allosteramers and uses thereof
US8221753B2 (en) 2009-09-30 2012-07-17 Tracon Pharmaceuticals, Inc. Endoglin antibodies
WO2011028952A1 (en) 2009-09-02 2011-03-10 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
KR20120104558A (en) 2009-11-05 2012-09-21 세파론 오스트레일리아 피티와이 엘티디 Treatment of cancer involving mutated kras or braf genes
SG182408A1 (en) 2010-01-11 2012-08-30 Alexion Pharma Inc Biomarkers of immunomodulatory effects in humans treated with anti-cd200 antibodies
MY171234A (en) 2010-02-24 2019-10-04 Immunogen Inc Folate receptor 1 antibodies and immunoconjugates and uses thereof
MX2012010148A (en) 2010-03-04 2013-01-22 Pfenex Inc Method for producing soluble recombinant interferon protein without denaturing.
WO2011123570A2 (en) 2010-04-01 2011-10-06 Pfenex Inc. Methods for g-csf production in a pseudomonas host cell
NZ603226A (en) 2010-04-30 2015-02-27 Alexion Pharma Inc Anti-c5a antibodies and methods for using the antibodies
EA201291328A1 (en) 2010-06-22 2013-10-30 Дзе Риджентс Оф Дзе Юниверсити Оф Колорадо, Э Боди Корпорейт ANTIBODIES TO C3d FRAGMENT OF COMPONENT 3
JP2012041316A (en) * 2010-08-23 2012-03-01 Akita Univ New peptide and molecular chaperon-inducing agent and anticancer agent
WO2012106634A1 (en) 2011-02-03 2012-08-09 Alexion Pharmaceuticals, Inc. Use of an anti-cd200 antibody for prolonging the survival of allografts
PL2672994T3 (en) 2011-02-11 2018-11-30 Merck Patent Gmbh Anti-alpha-v integrin antibody for the treatment of prostate cancer
WO2012122985A1 (en) * 2011-03-14 2012-09-20 University Of Copenhagen Antagonists of the interleukin- 1 receptor
IL303208A (en) 2011-04-01 2023-07-01 Immunogen Inc Methods for increasing efficacy of folr1 cancer therapy
US9073965B2 (en) 2011-04-12 2015-07-07 Temple University—Of the Commonwealth System of Higher Education Adiponectin receptor agonists and methods of use
US9988439B2 (en) 2011-12-23 2018-06-05 Nicholas B. Lydon Immunoglobulins and variants directed against pathogenic microbes
WO2013096948A1 (en) 2011-12-23 2013-06-27 Lydon Nicholas B Immunoglobulins and variants directed against pathogenic microbes
US20130216530A1 (en) * 2012-02-02 2013-08-22 Exagen Diagnostics, Inc. Methods for optimizing biological response modifier therapy using therapeutic drug monitoring of immunosuppressants
NZ726258A (en) 2012-08-31 2019-07-26 Immunogen Inc Antibodies and uses thereof to detect folate receptor 1
UA115789C2 (en) 2012-09-05 2017-12-26 Трейкон Фармасутікалз, Інк. Antibody formulations and uses thereof
TW202206465A (en) 2012-11-14 2022-02-16 美商再生元醫藥公司 Recombinant cell surface capture proteins
EP2968450A4 (en) 2013-03-15 2016-10-26 Angelica Therapeutics Inc Modified toxins
WO2014180490A1 (en) * 2013-05-10 2014-11-13 Biontech Ag Predicting immunogenicity of t cell epitopes
KR20230145514A (en) 2013-08-30 2023-10-17 이뮤노젠 아이엔씨 Antibodies and assays for detection of folate receptor 1
WO2015074048A1 (en) * 2013-11-18 2015-05-21 Siscapa Assay Technologies, Inc. Measurement of gamma-carboxylation of proteins
CA2943569C (en) 2014-03-27 2021-02-23 British Columbia Cancer Agency Branch T-cell epitope identification
CN106795506B (en) 2014-05-14 2020-11-27 达特茅斯学院理事会 Deimmunized lysostaphin and methods of use
PE20171135A1 (en) 2014-11-05 2017-08-09 Memorial Sloan Kettering Cancer Center METHODS TO SELECT A LINE OF T-CELLS AND DONOR THEM FOR ADOPTIVE CELLULAR THERAPY
US9926375B2 (en) 2014-11-12 2018-03-27 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof
US10155820B2 (en) 2014-11-12 2018-12-18 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof
KR101669140B1 (en) * 2015-04-28 2016-10-26 (주)케어젠 Peptides having Anti-obesity and Anti-Diabetes Effects and Use Thereof
US20180247011A1 (en) * 2015-09-01 2018-08-30 The Administrators Of The Tulane Educational Fund A method for cd4+ t-cell epitope prediction using antigen structure
RU2749865C2 (en) 2015-09-17 2021-06-17 Иммьюноджен, Инк. Therapeutic combinations containing anti-folr1 immunoconjugates
KR101897122B1 (en) * 2016-03-09 2018-09-10 주식회사 바이오펩 Peptides for treating inflammatory diseases and use thereof
US10913772B2 (en) * 2016-03-09 2021-02-09 Kine Sciences Co., Ltd. Peptide for preventing or treating inflammatory diseases and use thereof
EP3523467A4 (en) * 2016-10-04 2021-10-06 The Council of the Queensland Institute of Medical Research Peptide libraries and methods of use
KR101887577B1 (en) * 2016-10-19 2018-09-10 (주)케어젠 Peptides having Anti-obesity and Anti-Diabetes Effects and Use Thereof
GB201618432D0 (en) * 2016-11-01 2016-12-14 Matn Scient Ltd Detection and treatment of demyelinating diseases
WO2019089544A1 (en) 2017-11-01 2019-05-09 Tufts Medical Center, Inc. Bispecific antibody constructs and methods of use
US11802154B2 (en) 2017-12-20 2023-10-31 Alexion Pharmaceuticals, Inc. Humanized anti-CD200 antibodies and uses thereof
CN109206482B (en) * 2018-09-30 2021-12-10 福建蓝昊生物科技有限公司 Seaweed-derived short peptide for inhibiting digestive tract inflammation and application thereof
WO2020118011A1 (en) 2018-12-06 2020-06-11 Alexion Pharmaceuticals, Inc. Anti-alk2 antibodies and uses thereof
EP3757127A1 (en) * 2019-06-28 2020-12-30 Institute for Research in Biomedicine Deimmunized antibodies binding to alpha-4 integrin and uses thereof
CN110694056B (en) * 2019-10-25 2023-05-05 四川农业大学 FSH antigen, preparation method thereof and FSH vaccine containing FSH antigen
KR20210134245A (en) * 2020-04-29 2021-11-09 주식회사 원진바이오테크놀로지 Novel protein conjugate and its use of preventing or treating non-alcoholic steatohepatitis, obesity and diabetes
CN112457399B (en) * 2020-12-19 2023-09-01 上海佰君生物科技有限公司 Purification method of human immunoglobulin G
CN112480245B (en) * 2020-12-19 2023-08-18 上海佰君生物科技有限公司 Application of hydrophobic cyclic peptide ligand in purification of human immunoglobulin G

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2339430A (en) * 1997-05-21 2000-01-26 Biovation Ltd Method for the production of non-immunogenic proteins
WO2000034317A2 (en) * 1998-12-08 2000-06-15 Biovation Limited Method for reducing immunogenicity of proteins
WO2000042175A1 (en) * 1999-01-14 2000-07-20 Bolder Biotechnology Inc. Methods for making proteins containing free cysteine residues

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5801038A (en) 1984-05-29 1998-09-01 Genencor International Inc. Modified subtilisins having amino acid alterations
US5972682A (en) 1984-05-29 1999-10-26 Genencor International, Inc. Enzymatically active modified subtilisins
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
DK203187A (en) 1986-04-22 1987-10-23 Immunex Corp HUMAN G-CSF PROTEIN EXPRESSION
NO176799C (en) 1986-12-23 1995-05-31 Kyowa Hakko Kogyo Kk DNA encoding a polypeptide, recombinant plasmid that encodes and can express a polypeptide and method for producing this polypeptide
US4914031A (en) 1987-04-10 1990-04-03 Amgen, Inc. Subtilisin analogs
US4904584A (en) 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
CA1340810C (en) 1988-03-31 1999-11-02 Motoo Yamasaki Polypeptide derivatives of human granulocyte colony stimulating factor
JPH02503867A (en) 1988-04-15 1990-11-15 プロテイン　デザイン　ラブズ　インコーポレーテッド IL-2 receptor-specific chimeric antibody
US5075222A (en) 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GEP20022681B (en) 1989-01-31 2002-04-25 Aaronson Us Stuart A Protein KFG, Antibodies, Pharmaceutical Composition, Their Use, recombinant DNA, Cell, Method for Discoveries and Production of Proteins, Method for Stimulation of Epithelial Cells Growth
US5166322A (en) 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
KR100188532B1 (en) 1989-05-17 1999-06-01 스티븐 엠. 오드리 Multiply mutated subtilisins
US6143866A (en) * 1989-07-18 2000-11-07 Amgen, Inc. Tumor necrosis factor (TNF) inhibitor and method for obtaining the same
US5605690A (en) 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
US5945397A (en) 1989-09-05 1999-08-31 Immunex Corporation Purified p75 (type II) tumor necrosis factor receptor polypeptides
US5395760A (en) 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
EP0438310A1 (en) 1990-01-19 1991-07-24 Merck & Co. Inc. Method for producing recombinant immunoglobuline
US5986070A (en) 1990-04-06 1999-11-16 Amgen Inc. Production of biologically active NGF proteins
GB9107846D0 (en) 1990-04-30 1991-05-29 Ici Plc Polypeptides
DE4014750A1 (en) 1990-05-08 1991-11-14 Boehringer Mannheim Gmbh MUTEINE OF THE GRANULOCYTE-STIMULATING FACTOR (G-CSF)
DE4105480A1 (en) 1991-02-21 1992-08-27 Boehringer Mannheim Gmbh IMPROVED ACTIVATION OF RECOMBINANT PROTEINS
PL174721B1 (en) 1992-11-13 1998-09-30 Idec Pharma Corp Monoclonal antibody anty-cd2
JP3570516B2 (en) 1993-06-29 2004-09-29 カイロン コーポレイション Truncated keratinocyte growth factor (KGF) with increased biological activity
US5595721A (en) 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
US5618714A (en) 1993-12-15 1997-04-08 Eli Lilly And Company Methods for producing protein C
AU2191795A (en) 1994-03-23 1995-10-09 Alexion Pharmaceuticals, Inc. Method for reducing immune and hemostatic dysfunctions during extracorporeal circulation
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
CU22615A1 (en) * 1994-06-30 2000-02-10 Centro Inmunologia Molecular PROCEDURE FOR OBTAINING LESS IMMUNOGENIC MONOCLONAL ANTIBODIES. MONOCLONAL ANTIBODIES OBTAINED
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US6008328A (en) 1994-10-13 1999-12-28 Amgen Inc. Method for purifying keratinocyte growth factors
US5770577A (en) 1994-11-14 1998-06-23 Amgen Inc. BDNF and NT-3 polypeptides selectively linked to polyethylene glycol
US5869330A (en) 1995-06-05 1999-02-09 Whitehead Institute For Biomedical Research DNA encoding a novel serum protein produced exclusively in adipocytes
US6013256A (en) 1996-09-24 2000-01-11 Protein Design Labs, Inc. Method of preventing acute rejection following solid organ transplantation
EP1835030A1 (en) 1996-12-20 2007-09-19 Amgen, Inc. OB fusion protein compositions and methods
US5741772A (en) 1997-02-03 1998-04-21 Amgen Inc. Neurotrophic factor NNT-1
US6159468A (en) 1997-04-28 2000-12-12 Eli Lilly And Company Activated protein C formulations
HUP0001237A3 (en) 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders
AU2346900A (en) * 1998-11-30 2000-06-19 Eli Lilly And Company Erythropoietic compounds
AU778939B2 (en) 1999-01-07 2004-12-23 Emd Lexigen Research Center Corp. Expression and export of anti-obesity proteins as Fc fusion proteins

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2339430A (en) * 1997-05-21 2000-01-26 Biovation Ltd Method for the production of non-immunogenic proteins
WO2000034317A2 (en) * 1998-12-08 2000-06-15 Biovation Limited Method for reducing immunogenicity of proteins
WO2000042175A1 (en) * 1999-01-14 2000-07-20 Bolder Biotechnology Inc. Methods for making proteins containing free cysteine residues

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
ELIAS D J ET AL: "PHASE I CLINICAL COMPARATIVE STUDY OF MONOCLOMAL ANTIBODY KS1/4 AND KS1/4-METHOTREXATE IMMUNOCONJUGATE IN PATIENTS WITH NON-SMALL CELL LUNG CARCINOMA", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, USA, DE, vol. 50, no. 13, 1 July 1990 (1990-07-01), pages 4154 - 4159, XP000882813 *
FERSHT A ET AL: "PROTEIN ENGINEERING", TRENDS IN BIOCHEMICAL SCIENCES, ELSEVIER SCIENCE PUBLISHERS BV., AMSTERDAM, NL, vol. 17, no. 8, August 1992 (1992-08-01), pages 292 - 294, XP001148065, ISSN: 0376-5067 *
GILLIES S D ET AL: "HIGH-LEVEL EXPRESSION OF CHIMERIC ANTIBODIES USING ADAPTED CDNA VARIABLE REGION CASSETTES", JOURNAL OF IMMUNOLOGICAL METHODS, ELSEVIER SCIENCE PUBLISHERS B.V.,AMSTERDAM, NL, vol. 125, 1989, pages 191 - 202, XP002176400, ISSN: 0022-1759 *
GILLIES S ET AL: "Antibody-IL-12 fusion proteins are effective in SCID mouse models of prostate and colon carcinoma metastases", JOURNAL OF IMMUNOLOGY, AMERICAN ASSOCIATION OF IMMUNOLOGISTS, US, vol. 160, no. 12, 15 June 1998 (1998-06-15), pages 6195 - 6203, XP002106576, ISSN: 0022-1767 *
NUCCI M L ET AL: "STRATEGIES FOR DEALING WITH THE IMMUNOGENICITY OF THERAPEUTIC PROTEINS", HANDBOOK OF EXPERIMENTAL PHARMACOLOGY, SPRINGER VERLAG, BERLIN, XX, vol. 137, 1999, pages 59 - 88, XP001084754, ISSN: 0171-2004 *
PADLAN E A: "A POSSIBLE PROCEDURE FOR REDUCING THE IMMUNOGENICITY OF ANTIBODY VARIABLE DOMAINS WHILE PRESERVING THEIR LIGAND-BINDING PROPERTIES", MOLECULAR IMMUNOLOGY, ELMSFORD, NY, US, vol. 28, no. 4/5, 1 April 1991 (1991-04-01), pages 489 - 498, XP002020736, ISSN: 0161-5890 *
RIGGIN A ET AL: "SOLUTION STABILITY OF THE MONOCLONAL ANTIBODY-VINCA ALKALOID CONJUGATE, KS1/4-DAVLB", PHARMACEUTICAL RESEARCH, NEW YORK, NY, US, vol. 8, no. 10, 1 October 1991 (1991-10-01), pages 1264 - 1269, XP000986327, ISSN: 0724-8741 *
VARKI N M ET AL: "ANTIGENS ASSOCIATED WITH A HUMAN LUNG ADENOCARCINOMA DEFINED BY MONOCLONAL ANTIBODIES", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 44, no. 2, 1 February 1984 (1984-02-01), pages 681 - 687, XP000123140, ISSN: 0008-5472 *
WINTER G ET AL: "Humanized antibodies.", TRENDS IN PHARMACOLOGICAL SCIENCES. MAY 1993, vol. 14, no. 5, May 1993 (1993-05-01), pages 139 - 143, XP002307956, ISSN: 0165-6147 *

Also Published As

Publication number Publication date
PL362414A1 (en) 2004-11-02
CN1493052A (en) 2004-04-28
EP1366455B1 (en) 2008-07-02
CA2438652A1 (en) 2002-09-06
KR100899970B1 (en) 2009-05-28
EP1998266A2 (en) 2008-12-03
ES2309167T3 (en) 2008-12-16
WO2002069232A2 (en) 2002-09-06
CN100404673C (en) 2008-07-23
JP2004523754A (en) 2004-08-05
ZA200307324B (en) 2005-02-23
AU2002256624B8 (en) 2002-09-12
US20040180386A1 (en) 2004-09-16
AU2002256624B2 (en) 2007-12-06
EP1366455A2 (en) 2003-12-03
MXPA03007316A (en) 2003-12-04
KR20030075201A (en) 2003-09-22
WO2002069232A3 (en) 2003-02-13
ATE400030T1 (en) 2008-07-15
HUP0303199A2 (en) 2003-12-29
JP4279554B2 (en) 2009-06-17
US7430476B2 (en) 2008-09-30

Similar Documents

Publication Publication Date Title
EP1998266A3 (en) Method for identification of T-cell epitopes and use for preparing molecules with reduced immunogenicity
EP2210945A3 (en) Neisseria meningitidis antigens
EP1144998A3 (en) Neisseria genomic sequences and methods of their use
CA2290485A1 (en) Method for the production of non-immunogenic proteins
EP2287177A3 (en) Streptococcus agalactiae antigens I + II
EP2275551A3 (en) Neisserial antigenic peptides
WO2000056901A3 (en) Linear and circular expression elements
WO2003086308A3 (en) Compositions and methods for the diagnosis and treatment of herpes simplex virus infection
NZ508366A (en) Neisseria meningitidis antigens and compositions
EP2330129A3 (en) Anti-TNF antibodies, compositions, methods and uses
EP1741782A9 (en) Immunogenic polypeptides encoded by MAGE minigenes and uses thereof
BR0010361A (en) Genetic sequences of neisseria and use of these
EP1067182A8 (en) Secretory protein or membrane protein
AU2002302921A1 (en) Gonococcal proteins and nucleic acids
EP2316486A3 (en) Cripto blocking antibodies and uses thereof
EP2202243A3 (en) Antigen binding domains from fish
EP2277893A3 (en) Compounds and methods for treatment and diagnosis of chlamydial infection
EP2311952A3 (en) Antibodies to MRT-1 protein or fragments thereof
WO2001062893A3 (en) Compounds and methods for diagnosis and immunotherapy of tuberculosis
EP2287194A3 (en) Antibodies binding to ephb4 for inhibiting angiogenesis and tumor growth
WO2003016915A8 (en) Tumor specific oligosaccharide sequences and use thereof
WO2003016464A3 (en) Cancer specific oligosaccharide sequences and use thereof
WO2003041560A3 (en) Compounds and methods for treatment and diagnosis of chlamydial infection
EP1297147B8 (en) Compositions for the diagnosis and treatment of herpes simplex virus infection
EP1230932A3 (en) Use of antibodies for anticancer vaccination

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20080701

AC Divisional application: reference to earlier application

Ref document number: 1366455

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

RIN1 Information on inventor provided before grant (corrected)

Inventor name: WILLIAMS, STEPHEN

Inventor name: JONES, TIM, DR.

Inventor name: HAMILTON, ANITA, A.

Inventor name: CARTER, GRAHAM

Inventor name: CARR, FRANCIS, JOSEPH, DR.

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

17Q First examination report despatched

Effective date: 20090513

AKX Designation fees paid

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20100420